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ORIGINAL ARTICLE

Plasmid injection and application of electric pulses alter
endogenous mRNA and protein expression in B16.F10
mouse melanomas
LC Heller1, YL Cruz2, B Ferraro2, H Yang2 and R Heller1
1

Department of Medical Laboratory and Radiation Sciences, Frank Reidy Research Center for Bioelectrics,
Old Dominion University, Norfolk, VA, USA and 2Department of Molecular Medicine, University of South
Florida College of Medicine, Tampa, FL, USA
The application of electric pulses to tissues causes cell membrane destabilization, allowing exogenous molecules to enter the cells.
This delivery technique can be used for plasmid gene therapy. Reporter gene expression after plasmid delivery with eight
representative published protocols was compared in B16.F10 mouse melanoma tumors. This expression varied significantly based on
the pulse parameters utilized for delivery. To observe the possible influence of plasmid injection and/or pulse application on
endogenous gene expression, levels of stress-related mRNAs 4 and 24 h after delivery were determined by PCR array. Increases in
mRNA levels for several inflammatory chemokines and cytokines were observed in response to plasmid injection, electric pulses alone
or the combination. This upregulation was confirmed by individual real-time reverse transcription TaqMan PCR assays. Proteins were
extracted at the same time points from identically treated tumors and inflammatory protein levels were assayed by enzyme-linked
immunosorbent assay and by a custom multiplex bead array. Increases in inflammatory protein levels generally paralleled mRNA
levels. Some differences were observed, which may have been due to differing expression kinetics. The observed upregulated
expression of these cytokines and chemokines may aid or inhibit the therapeutic effectiveness of immune-based cancer gene therapies.
Cancer Gene Therapy (2010) 17, 864–871; doi:10.1038/cgt.2010.43; published online 13 August 2010
Keywords: electroporation; inflammation; melanoma

Introduction

The use of in vivo electroporation (EP) as a therapeutic
gene delivery approach has been successfully used in a
variety of applications including cancer therapy and the
regulation of protein levels to enhance or reduce protein
function. For therapeutic cancer applications, plasmids
evaluated for gene therapy encode the same types of genes
or complementary DNAs tested using viral delivery
methods, including immune modulators, cell cycle regulators, suicide genes, anti-angiogenic genes and genes
encoding toxins or tumor antigens. Diverse delivery
protocols varying in pulse parameters and in electrode
configurations have been described.1
Many of the therapeutic studies of in vivo intratumor
EP in experimental cancer models test the delivery of
plasmids encoding immune modulators. These studies
may demonstrate significant tumor regression, indicating
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that the delivered genes or complementary DNAs are
potentially effective as antitumor agents. A limited
number of these studies have demonstrated long-term,
complete tumor regression, including studies delivering
plasmids encoding interleukin (IL)-12,2–6 interferon (IFN)
a,7,8 IL-159 and IL-2110 as single agents. Complete tumor
regression was observed after delivery of combinations of
plasmids encoding IL-6 and IL-15,11 granulocyte-macrophage colony-stimulating factor (GM-CSF) and B7.1,12
or IL-12 and B7.1.13 Intratumor EP of a plasmid
encoding the human IL-12 complementary DNAs for
melanomas has been successful therapeutically in a
phase I clinical trial.14 Intratumor delivery of a plasmid
encoding the human IL-2 complementary DNA to
melanomas has also reached clinical trials, although
efficacy has not yet been reported.15 These studies support
the idea that immune modulators may be efficacious as
cancer therapies.
Inflammation induced by the combination of plasmid
delivery and electric pulses has been described in several
tissues, most commonly muscle. Local inflammatory
responses have been observed between 24 h and 7 days
after plasmid injection16 or delivery of pulses alone in
rat,17 mouse18–22 and pig23 muscle. The combination
of vector plasmid and pulses may induce higher levels
of inflammation than plasmid alone.20,24,25 In skin,
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no significant histological changes were observed up to
5–7 days after delivery of pulses alone.26 In another study,
minimal to mild inflammation was observed.19 Tumors
have also been studied. In B16.F10 mouse melanomas, a
strong infiltration of polymorphonuclear cells, monocytes
and some lymphocytes was observed 24 h after vector
plasmid delivery.27 In the RM4 rat bladder cancer
model, macrophages were observed in the tumor periphery 3 days after electrically mediated plasmid delivery.28
When plasmid DNA is present, the observed inflammation may be due in part to the induction of an
inflammatory response to CpG motif DNA. The mammalian TLR9 receptor recognizes double-stranded DNA
that is not CpG methylated as a danger signal.29 As
plasmid DNA is produced bacterially and is not CpG
methylated, an inflammatory immune response may be
produced in response to its introduction, particularly to B
and plasmacytoid pre-dendritic cells. Secreted immune
modulators may include IFNg, IL-1b, IL-6, IL-8, IL-10,
IL-12, IL-18, tumor necrosis factor (TNF) a, IFN-ginducible protein 10 (IP-10), macrophage inflammatory
protein (MIP)-1b and GM-CSF. This inflammatory
response can be reduced or eliminated by deleting CpG
motifs from the plasmid.30
Approximately 50 different EP protocols for in vivo
plasmid delivery to tumors have been described. These
studies have differed in the electrode for delivery, tumor
type, animal model, reporter protein and the time point
chosen for assessment. No direct comparison of reporter
gene expression after plasmid delivery using these protocols has been reported. One purpose of this study is to
clarify the relationship between EP parameters and
transgene expression by using a single commercially
prepared reporter plasmid in a single tumor model at a
single time point. In addition, mRNA and protein levels
of endogenous genes regulated by intratumor plasmid
vector DNA injection, by the delivery of two different
types of electric pulses to the tumor, and to the
combination will be quantified. Endogenous genes
regulated by delivery may be important considerations
when designing therapeutic antitumor protocols.

Materials and methods

Tumor and animal model
All procedures were approved by the Animal Use and
Care Committee of the University of South Florida
College of Medicine. In all, 106 B16.F10 (ATCC CR6475)
mouse melanoma cells in 50 ml phosphate-buffered saline
were injected subcutaneously in the left flank of female
7- to 8-week-old C57Bl/6 mice (Jackson Laboratories, Bar
Harbor, ME). Tumors were allowed to grow 8 days to a
diameter of approximately 4 mm before plasmid delivery.
Plasmid DNA preparation
gWizLuc, which encodes the luciferase gene driven by the
cytomegalovirus (CMV) promoter, and gWizBlank, a
plasmid vector that does not encode a transgene, were
commercially prepared (Aldevron, Fargo, ND) and sus-

pended to a concentration of 1 mg ml–1 in sterile injectable
saline. Endotoxin levels were o0.1 EU mg–1 plasmid.

EP delivery
Mice were anesthetized using a mixture of 2.5%
isoflurane and 97.5% O2. Tumors were injected with
50 ml plasmid DNA and pulsed immediately as described
in each figure at a frequency of 1 Hz using a T820
Electrosquare porator (BTX, Holliston, MA). Delivery
was performed with caliper electrodes moistened with
electrode paste or with a six-needle array per each
published protocol. An autoswitcher was used for delivery
with the six-needle array. At the time points indicated
after delivery, mice were humanely killed, tumors
removed and snap frozen on dry ice.
Reverse transcription PCR assays
For PCR assays, RNA was extracted from tumors using
Trizol (Invitrogen, Carlsbad, CA), purified using RNeasy
columns (Qiagen, Valencia, CA) and quantified RNA
from four tumors per group was pooled. mRNA levels
were determined using Mouse Stress and Toxicity SYBR
PCR arrays (SABiosciences, Frederick, MD) after reverse
transcription per manufacturer’s instructions. Relative
quantification was performed by comparison with the
housekeeping genes b-actin and glyceraldehyde 3-phosphate dehydrogenase using the DDCt method. TaqMan
one-step RT-PCR was performed for GM-CSF, Cxcl10,
IL-1a, IL-1b, IL-6, b-actin and glyceraldehyde 3-phosphate dehydrogenase to confirm changes in mRNA levels
(TaqMan Gene Expression Assays, Applied Biosystems,
Foster City, CA). As untreated tumors did not express
GM-CSF endogenously, total lung RNA was used as a
positive control.
Protein assays
For luciferase quantification, the tumors were weighed,
homogenized and enzyme activity in extracts was normalized to the tumor weight.31 For enzyme-linked immunosorbent assays (ELISAs) and multiplex bead arrays,
tumors were homogenized in phosphate-buffered saline
containing protease inhibitors. Homogenates were centrifuged to remove cell debris. Bicinchoninic acid assays
(Pierce Biotechnology, Rockford, IL) were performed and
samples normalized to 1 mg ml–1 total protein. ELISAs
were performed per manufacturer’s instructions (R&D
Systems, Minneapolis, MN). A custom multiplex bead
array including mouse IL-1a, IL-1b, IL-4, IL-6, IL-10,
MIP-1a, MIP-1b, TNFa and GM-CSF was constructed
and samples assayed using a Bio-Plex System (Bio-Rad,
Hercules, CA) per manufacturer’s instructions.
Statistical analysis
Analysis of reporter gene expression after electrically
mediated plasmid delivery to B16.F10 mouse melanomas
was completed using analysis of variance. A post hoc
Dunnett’s test was used to adjust for multiple comparisons with one control group (injection of gWizLuc
without EP). Analysis of cytokine protein expression was
completed using analysis of variance. A post hoc Fisher’s
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Least Significant Difference test was used to adjust for
multiple comparisons.

Results

Reporter gene expression
Eight published EP protocols for intratumor delivery
were compared in the subcutaneous B16. F10 mouse
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Figure 1 Reporter gene expression 24 h after electrically mediated
plasmid delivery to B16.F10 mouse melanomas. In all, 50 mg
gWizLuc (Aldevron) was delivered to melanomas using various EP
protocols: 1, ten 50 ms 800 V cm–1 pulses with a caliper electrode;59
2, eight 20 ms 500 V cm–1 pulses with a caliper electrode;54 3, eight
50 ms 66 V cm–1 pulses with a six-needle array;5 4, six 50 ms
167 V cm–1 pulses with a caliper electrode;60 5, six 0.1 ms 1300 V cm
pulses with a six-needle array;2 6, one 100 ms 667 V cm–1 pulse with
a caliper electrode;32 7, two 20 ms 450 V cm–1 pulses with a caliper
electrode;3 8, five 10 ms 400 V cm–1 pulses with a caliper electrode.55
Activity was normalized to tumor weight. **Po0.01, ***Po0.001 with
respect to injection alone, n ¼ 12–18 per group. Values represent
mean±standard error.

melanoma model using a plasmid-encoding luciferase as a
reporter (gWizLuc, Aldevron). These protocols varied
with respect to electrode, and pulse amplitude, length and
number. At 24 h, luciferase expression was determined
(Figure 1). Using this specific reporter and time point,
four delivery protocols produced expression that was
significantly higher than expression from plasmid injection. Two protocols suggested increased expression, while
two protocols exhibited no substantial expression above
plasmid injection alone.

Endogenous mRNA levels
To determine whether in vivo EP can effect endogenous
gene expression, two very different pulse protocols from
Table 1 were compared. One protocol included six
relatively short (100 ms) pulses at a field strength of
1300 V cm–1 using a six-needle array electrode (EP5).2
Delivery with this protocol produced low-level and
reproducible reporter gene expression. A second protocol
varied markedly in that a single relatively long (100 ms)
pulse at 667 V cm–1 was delivered with a caliper electrode
(EP6).32 Delivery with this protocol produced high levels
of reporter gene expression.
Gene expression was observed after delivery of saline or
plasmid vector DNA with each pulse protocol and
compared with untreated tumors and tumors injected
with plasmid DNA without EP. At 4 and 24 h after
delivery, mice were killed and tumors excised. Pooled
RNA from tumors in each experimental group (n ¼ 4) was
subjected to two-step real-time SYBR RT-PCR performed using Mouse Stress and Toxicity SYBR PCR
arrays (SABiosciences). The gene groups contained in the
array included oxidative or metabolic stress, heat shock,
proliferation and carcinogenesis, growth arrest and
senescence, necrosis or apoptosis, and inflammation.
Each array was then repeated with a second group of
four tumors. The fold changes in expression were
determined by comparison with the housekeeping genes
b-actin and glyceraldehyde 3-phosphate dehydrogenase.
No downregulated mRNA levels were observed.
The inflammation group contained the highest number

Table 1 Mean fold changes in mRNA expression by reverse transcription and PCR array with respect to untreated control tumors after plasmid
delivery to B16.F10 mouse melanomas
Time point (h)

Ccl21b

Ccl3/MIP-1a

Ccl4/MIP-1b

Cxcl10/IP-10

IL-1a

IL-1b

IL-6

IL-18

iNos

Serpine1/PAI-1

4
24
4
24
4
24
4
24
4
24

2.2
15.5
11.7
4.4
11.5
3.7
1.7
13.7
2.0
1.1

111.4
14.4
2.4
3.7
7.1
2.7
4.3
10.4
6.1
3.2

512.0
46.9
2.5
2.5
31.5
2.7
6.3
29.3
81.6
28.8

19.0
6.5
2.8
2.8
25.6
2.1
46.8
11.1
28.8
3.4

26.0
4.8
6.1
3.4
23.8
3.4
10.2
3.5
11.3
1.5

76.1
7.5
6.7
3.3
62.9
7.5
16.6
7.3
71.0
7.7

8.9
1.3
3.4
1.6
36.1
1.7
32.0
1.7
28.8
2.1

35.5
73.5
1.5
6.6
6.8
5.9
2.8
26.5
10.2
6.3

48.5
12.0
3.1
3.1
15.2
1.5
17.8
18.7
9.8
6.5

7.7
11.7
18.4
15.7
102.2
22.6
1.9
40.1
132.5
16.6

gWizBlank only
Saline+EP5
Saline+EP6
gWizBlank+EP5
gWizBlank+EP6

Abbreviations: IL, interleukin; IP-10, inducible protein 10; MIP, macrophage inflammatory protein; PAI-1, plasminogen activator
inhibitor-1.
EP5, six 100 ms 1300 V cm–1 pulses delivered with a six-needle array electrode; EP6, one 100 ms 667 V cm–1 pulse delivered with
caliper electrodes.
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Table 2 Fold changes in mRNA expression by reverse transcription and TaqMan PCR with respect to untreated control tumors after plasmid
delivery to B16.F10 mouse melanomas

gWizBlank only
Saline+EP5
Saline+EP6
gWizBlank+EP5
gWizBlank+EP6

Time point (h)

Cxcl10/IP-10

IL-1a

IL-1b

IL-6

Serpine1/PAI-1

4
24
4
24
4
24
4
24
4
24

24.8
3.2
1.4
2.0
13.7
0.3
35.8
2.1
21.4
2.6

7.7
1.0
1.5
0.2
14.8
2.0
4.5
2.7
14.4
3.2

7.6
1.1
2.0
1.7
68.6
6.5
7.9
4.2
40.0
9.1

39.0
1.2
3.6
2.4
128.0
2.3
26.0
3.9
128.0
5.6

0.7
0.3
1.2
0.9
2.5
0.8
1.1
1.1
1.7
1.0

Abbreviations: IL, interleukin; IP-10, inducible protein 10; PAI-1, plasminogen activator inhibitor-1.

Table 3 Cytokine expression measured by ELISA after plasmid
delivery to B16.F10 mouse melanomas (mean±s.d.)

Untreated
gWizBlank only
Saline+EP5
Saline+EP6
gWizBlank+EP5
gWizBlank+EP6

Time
point
(h)

IL-1b
(pg mg–1 total
protein)

IL-6
(pg mg–1 total
protein)

4
24
4
24
4
24
4
24
4
24

4.5±5.9
112.5±50.0
1.9±2.2
12.0±5.8
3.0±3.7
57.6±24.5
7.8±4.7
219.0±126.4***
8.6±5.9
156.3±111.7*
10.0±7.0

21.2±9.8
245.9±126.8
32.1±14.5
32.6±9.9
10.1±8.7
141.2±106.5
10.1±8.8
1644.7±868.7***
45.0±3.5
996.8±865.0**
49.2±20.8

Abbreviations: ELISA, enzyme-linked immunosorbent assay;
IL, interleukin.
*po0.05, **po0.01, ***po0.001.

of upregulated mRNA levels across the delivery groups.
Within this group, mRNAs for Ccl21b, Ccl3/MIP-1a,
Ccl4/MIP-1b, Cxcl10/IP-10, IL-1a, IL-1b, IL-6, IL-18,
iNos and Serpine1/plasminogen activator inhibitor-1
(PAI-1) were upregulated in response to at least one
delivery condition, while mRNA levels for Csf2/GMCSF, Lta/TNFb, MIF and nuclear factor k-B1 were
unchanged.
In response to plasmid DNA injection alone, the array
results indicated that most of the mRNA levels were
upregulated by 4 h after delivery. This is likely a response
to CpG motif DNA. By 24 h, expression was considerably
reduced. Saline injection followed by EP protocol EP5
alone appeared to induce upregulation for Ccl21b and
Serpine1/PAI-1, while saline injection with protocol EP6
appeared to upregulate Ccl21b, Cxcl10/IP-10, IL-1a,
IL-1b, IL-6, iNos and Serpine1/PAI-1 to higher levels.
The detected increases in relative levels of mRNAs were
tested by a one-step TaqMan RT-PCR for a subset of
targets, including IP-10, IL-1a, IL-1b, IL-6 and Serpine1
(Table 2). The specific PCR quantifications for IP-10,

IL-1a, IL-1b, and IL-6 in general tended to support the
increases in mRNA levels detected by the PCR array.
However, increased levels of Serpine1 observed with the
PCR array were the not confirmed with the individual
PCR.

Endogenous protein levels
To determine whether the observed changes in mRNA
levels resulted in concomitant changes in protein levels, a
subset of proteins was assayed using ELISAs and multiplex bead arrays. For these experiments, deliveries were
performed and samples taken as described for the RNA
experiments. For each delivery group, four tumors were
assayed individually.
Using ELISAs for mouse IL-1b and IL-6, low
endogenous levels of each cytokine were present in
untreated tumors (Table 3). Four hours after delivery,
IL-1b protein levels in tumors from the group receiving
plasmid injection tended to be higher than the levels in
untreated tumors. Protein levels in tumors receiving pulse
protocol EP5 with saline also increased, but this increase
appeared to be greater after delivery of saline with pulse
protocol EP6. In groups receiving the combination of
plasmid DNA and either EP protocol, levels were
significantly higher than in untreated tumors. At 4 h,
IL-6 protein levels also increased after plasmid injection,
but this increase was not statistically greater than
untreated tumors. Similar to IL-1b, the increase in IL-6
levels tended to be higher after saline delivery with
protocol EP6 than with EP5. With the combination of
plasmid and EP, these levels were statistically discernable
with either EP protocol. For both cytokines, increased
levels were reduced by 24 h.
Multiplex bead arrays were performed for mouse
MIP-1a, MIP-1b, IL-1a, IL-1b and IL-6 per manufacturer’s instructions (Table 4). Three cytokines that may be
upregulated in response to CpG motif DNA (IL-4, IL-10
and TNFa) were also tested. At the tested time points,
IL-4 and TNFa were not detected in untreated tumors
and were undetected or detected at insignificant levels
in the delivery groups (data not shown). Detectable
endogenous levels of the remaining protein targets,
particularly IL-1a and MIP-1a, were present in untreated
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Table 4 Cytokine expression measured by multiplex bead array after plasmid delivery to B16.F10 mouse melanomas (mean±s.d.)
Time
point (h)

Untreated
gWizBlank only
Saline+EP5
Saline+EP6
gWizBlank+EP5
gWizBlank+EP6

4
24
4
24
4
24
4
24
4
24

Ccl3/MIP-1a
(pg mg–1 total
protein)

Ccl4/MIP-1b
(pg mg–1 total
protein)

IL-1a
(pg mg–1 total
protein)

IL-1b
(pg mg–1 total
protein)

IL-6
(pg mg–1total
protein)

IL-10
(pg mg–1 total
protein)

67.9±27.6
453.4±38.1**
422.5±136.5*
30.0±26.0
157.7±121.2
43.4±18.8
28.5±28.0
874.8±339.3***
430.4±139.4**
398.2±111.0*
226.2±61.4

10.9±6.6
130.7±159.5
159.8±120.1
4.3±3.8
18.2±14.9
3.0±5.2
0.7±1.2
369.8±221.1***
119.7±56.5
206.4±110.8
75.6±44.9

44.2±25.6
214.0±115.3***
32.4±8.7
151.8±44.4*
8.3±1.7
73.1±36.0
8.4±4.0
114.3±41.2
10.0±6.2
100.5±73.8
13.3±10.2

11.1±10.0
104.3±31.8
14.2±4.9
13.9±7.4
3.1±3.6
34.9±12.4
7.6±10.0
221.6±130.2***
8.0±7.3
110.0±79.1
6.1±7.2

2.5±2.5
47.3±18.3
4.6±2.5
6.3±2.1
0.7±0.9
61.1±65.1
1.4±1.5
544.1±202.3***
6.4±2.2
299.0±312.4*
7.1±3.4

2.4±1.2
27.8±16.0**
13.5±3.1
2.2±2.0
4.3±1.7
1.5±0.5
0.4±0.7
47.7±19.1***
8.0±4.1
24.1±3.4**
9.7±2.8

Abbreviations: IL, interleukin; MIP, macrophage inflammatory protein.
*po0.05, **po0.01, ***po0.001.

tumors. After plasmid injection, levels of MIP-1a, IL-1a
and IL-10 reached statistical significance. When saline
was delivered with EP5 pulses, only IL-1a levels increased
significantly at 4 h. No other statistically significant
increases in protein levels to pulses alone were observed.
However, with the combination of EP5 and plasmid
DNA, significant increases in IL-1b, IL-6, MIP-1a and
MIP-1b proteins were observed at 4 h. When plasmid
DNA was combined with EP6, MIP-1a, IL-6 and IL-10
were significantly increased at 4 h.

Discussion

Using reporter gene expression 24 h after electrically
mediated delivery, the level of transgene expression varied
up to 92-fold over plasmid injection alone after delivery
with different EP protocols. For some groups, no
statistical increase in reporter gene expression was
observed after delivery. For these protocols, reporter
gene expression may not be detectable at this time point.
Alternatively, the reduction in transmembrane potential
necessary for membrane permeability may not have been
reached. These results clearly indicate that the level of
therapeutic transgene expression can be controlled by
the EP protocol with which the plasmid is delivered.
Although the expression levels varied significantly, it is
difficult to make any generalizations concerning the
relative usefulness of each pulse type. The therapeutic
gene delivered and its desired level of expression should
influence the pulsing protocol used for delivery, along
with other methods used in the control of transgene
expression, such as the use of alternative plasmid
promoters.
Increases in levels of several inflammatory mRNAs
were observed particularly after plasmid injection, application of pulse protocol EP6 or the combination of
plasmid DNA with either pulse protocol. Although
changes in mRNA levels were confirmed using individual
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PCRs, particularly at 410-fold increase on the array, the
precise fold change in expression was not necessarily
confirmed. Lower levels of upregulation were not
necessarily reproducible, particularly at the 24-h time
point. This may be due to the differences in specific
sequence targets and detection chemistries between the
two PCR detection methods.
Although proteins tended to be upregulated when the
mRNA levels were upregulated, the specific levels did not
necessarily correlate. It appeared that any manipulation
of the tumor-induced short-term IL-1a expression. For
IL-1b, the array very closely reproduced the results of the
ELISA assay. Interestingly, while the pattern of expression was similar for IL-6, the multiplex quantified levels
were clearly lower than the ELISA quantified levels. After
the array was performed, the ELISA was repeated on the
same samples and the ELISA values were confirmed. This
discrepancy between the two protein assays may be due to
differing target affinities of the antibodies used in the
respective assays. However, each assay indicated that IL-6
in particular was upregulated synergistically in response
to combination delivery.
IL-10 levels were significantly increased at 4 h after any
delivery containing plasmid DNA, indicating that a CpG
motif DNA effect was responsible. The expression of
the chemokines MIP-1a and MIP-1b tended to be longer
than cytokines expression, continuing through 4 and 24 h.
Although MIP-1a, MIP-1b, IL-1b, IL-6 and IL-10
protein levels were increased after delivery by both EP
protocols, expression tended to be higher after plasmid
delivery with EP5 than with EP6. This conflicts with the
observed mRNA levels, in which detected mRNA was
much higher after combination delivery with EP6 than
with EP5. These discrepancies may be due to the
particular time points chosen for the assays; changes in
protein levels may occur at different time points. Also,
protein levels may not necessarily directly depend on
mRNA levels. For example, both mRNA and protein
stability may affect protein levels33 and protein synthesis
may be regulated.34
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In a study of pulse delivery alone in mouse muscle,
increased levels of several mRNAs encoding proinflammatory modulators, including MIP-1a, MIP-1b, IP-10,
IL-6, iNos and GM-CSF were observed by microarray
2 and 4 h after delivery.21 With the exception of GM-CSF,
the data presented here confirm this upregulation in a
tumor model at 4 h. As in tumors, the cytokine mRNA
levels decreased to background by 24 h. However,
a difference in chemokine mRNA levels was observed.
In muscle, these levels decreased to background more
quickly than in tumor tissue. In a study of EP delivery of
a low concentration of plasmid DNA to rodent muscle,
no changes in expression of mRNAs involved in an
inflammatory response were observed by microarray
analysis at time points of 4 h, 48 h and 3 weeks. However,
an infiltration of mononuclear cells was observed
histologically at 48 h,35 suggesting the presence of an
inflammatory response. Cytokine protein expression after
EP of plasmid to mouse lung in bronchial alveolar lavage
fluid was tested 24 h after delivery. No upregulation of
IL-6, TNFa, IFNg or IL-12 was observed.36 The IL-6
results presented here confirm this observation, since by
24 h all observed increases in mRNA and protein levels
had decreased to insignificance. In an array analysis of EP
pulses to a human melanoma cell line, no significant
increase in inflammatory gene expression was observed.37
This is not unexpected because of the absence of immune
cells in this in vitro study.
The CMV promoter is commonly used for gene therapy
because it induces high levels of transcription in many
tissues. In vitro, transcription from this promoter
is cytokine regulated, particularly by IFNg and
TNFa,38–43 although other cytokine regulators have been
described. In mice, regulation of CMV promoter expression has been correlated to serum TNFa44 and IL-12
levels.45 Lung expression has been correlated to TNFa,
IL-12 and IFNg expression in bronchoalveolar lavage
fluid.46 The effect on expression may be dependent on the
tissue type.45 In this study, low but consistent levels of
TNFa were observed in all tumor groups at the tested
time points, limiting any conclusions concerning differential regulation in this model. IL-1b upregulates CMVdriven transcription42,43 in some cell types. Although the
combination of plasmid with EP5 induced higher levels of
IL-1b than EP6, reporter gene expression driven by the
CMV promoter was considerably lower. This does not
support IL-1b upregulation of the promoter, however,
there are many additional variables that would affect
transcription. IL-10 has been observed to downregulate
CMV-regulated transcription.43 In the case of IL-10,
EP5 induces higher levels of IL-10 than EP6, and this
downregulation could account for the reduced luciferase
activity. Once again, there are many additional variables
to be considered.
Inflammation induced by EP acts as a vaccine adjuvant
after muscle delivery of antigen-encoding plasmids.21,23,47–50 Changes in CD3 þ peripheral blood
lymphocyte levels have also been observed in macaques
after plasmid DNA immunization in combination with
EP.51 It is possible that the induction of these immune

modulators can also increase the effectiveness of cancer
immunotherapies by the induction of a specific antitumor
immune response.52 This endogenous cytokine induction
may enhance natural killer cell activation, producing a
direct antitumor effect. Antigen-presenting cells could
potentially be stimulated, which would aid in the
induction of an immune response by the protein expressed
from the delivered therapeutic gene. The electric pulses
may induce tumor cell damage that may make tumor
antigens available to the immune response. Interestingly,
an observable8,9,53–57 or statistically significant27,58 effect
on tumor growth has been observed after EP delivery
of non-coding control plasmids when compared with
untreated tumors. This effect may be due to the induction
of gene expression, including the immune modulators
described here. It is also possible that some induced
cytokines may work in opposition to the induction of a
specific immune response, for example, the suppressive
cytokine IL-10. The production of appreciable levels of
these immune modulators should be considered when
designing any EP-based antitumor therapy.
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